Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy


23 Nov 2019


Poster display session


Tumour Site

Breast Cancer


Kartika Taroeno Hariadi


Annals of Oncology (2019) 30 (suppl_9): ix1-ix8. 10.1093/annonc/mdz416


K.W. Taroeno Hariadi1, R.S. Pudyasari2, L. Choridah3, T. Aryandono4

Author affiliations

  • 1 Hematology-medical Oncology, Internal Medicine, Gadjah Mada University/Dr. Sardjito General Hospital, 55281 - Yogyakarta/ID
  • 2 Internal Medicine, Div.Hematology-Oncology, 55281 - Yogyakarta/ID
  • 3 Radiology, Breast Imaging, 55281 - Yogyakarta/ID
  • 4 Surgery, Surgical Oncology, Gadjah Mada University/Dr. Sardjito General Hospital, 55281 - Yogyakarta/ID


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 16P


NAFLD is a condition commonly found in breast cancer. This study aims at investigating risk factors, and prognostic impact of NAFLD in hormone-positive breast cancer receiving adjuvant hormonal treatment.


We retrospectively investigated hormone-positive, HER-2-negative, non-metastatic breast cancer patients, diagnosed since January 2010 - December 2018. All patients received hormonal treatment either tamoxifen (Tam), aromatase inhibitor (AI), or tamoxifen followed by aromatase inhibitor (Tam+AI). Clinical data on metabolic profiles (BMI, waist circumference, cholesterol, triglyceride, LDL, HDL, diabetes, or metabolic syndrome [MS]) were collected. Fatty liver displayed by USG. NAFLD diagnosed during hormonal treatment was analyzed based on metabolic risk factors, type of hormonal treatment, and disease-free survival (DFS).


There were 146 eligible patients. MS was detected in 44.5%, and obesity was in 11 % patients. Tam were used in 44.5% patients, whereas Tam+AI in 21.2%, and AI in 34.2%. NAFLD was diagnosed in 31.5% patients. There were significant association between obesity (OR = 3.20; 95%CI 1.12- 9.31; p = 0.024); waist circumference ≥ 80 cm (OR = 7.30; 95%CI 2.43-21.93; p = 0.000); triglyceride ≥ 150 mg/dL (OR = 2.19; 95% CI 1.05-4.56; p = 0.035); HDL ≤ 40 mg/dl (OR = 2.58; 95% CI 1.06-6.32; p = 0.03); MS (OR = 2.65; 95% CI 1.29-5.43; p = 0.007) with arising of NAFLD. Multivariate analysis showed that waist circumference was the strongest predictor to NAFLD (HR 5.92, 95% CI 1.7-19.8; p = 0.004). NAFLD was detected more frequently in tamoxifen-use patients (36.8%) compare to AI (16.6%) (OR = 1.94; 95% CI = 0.90-4.19; p < 0.08). Interestingly, there were less progression events in patients with NAFLD compared to non-NAFLD (23.9% vs. 40%; OR = 0.47, 95% CI 0.2-1.04; p = 0.058). Median survival time was 64 months in non-NAFLD; whereas in NAFLD group the median survival was not reached (HR = 1.813, 95% CI 0.93-3.55; p = 0.08).


Waist circumference predicts NAFLD in breast cancer during adjuvant hormonal therapy. NAFLD patients tend to have longer DFS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.